JP2022514385A5 - - Google Patents
Info
- Publication number
- JP2022514385A5 JP2022514385A5 JP2021535679A JP2021535679A JP2022514385A5 JP 2022514385 A5 JP2022514385 A5 JP 2022514385A5 JP 2021535679 A JP2021535679 A JP 2021535679A JP 2021535679 A JP2021535679 A JP 2021535679A JP 2022514385 A5 JP2022514385 A5 JP 2022514385A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- independently
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024094279A JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784229P | 2018-12-21 | 2018-12-21 | |
| US201862784222P | 2018-12-21 | 2018-12-21 | |
| US62/784,229 | 2018-12-21 | ||
| US62/784,222 | 2018-12-21 | ||
| PCT/US2019/067953 WO2020132504A1 (en) | 2018-12-21 | 2019-12-20 | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094279A Division JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514385A JP2022514385A (ja) | 2022-02-10 |
| JP2022514385A5 true JP2022514385A5 (enExample) | 2022-11-18 |
| JP7692830B2 JP7692830B2 (ja) | 2025-06-16 |
Family
ID=69591712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535679A Active JP7692830B2 (ja) | 2018-12-21 | 2019-12-20 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
| JP2024094279A Pending JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094279A Pending JP2024107296A (ja) | 2018-12-21 | 2024-06-11 | ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220372067A1 (enExample) |
| EP (1) | EP3898646B1 (enExample) |
| JP (2) | JP7692830B2 (enExample) |
| KR (1) | KR20210107050A (enExample) |
| CN (1) | CN113195512A (enExample) |
| AU (2) | AU2019403415B2 (enExample) |
| BR (1) | BR112021012242A2 (enExample) |
| CA (1) | CA3124371A1 (enExample) |
| IL (1) | IL284183A (enExample) |
| MX (2) | MX2021007504A (enExample) |
| TW (2) | TWI848034B (enExample) |
| WO (1) | WO2020132504A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| KR20250174100A (ko) | 2018-12-05 | 2025-12-11 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| WO2020132504A1 (en) * | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| US20230250129A1 (en) * | 2020-06-24 | 2023-08-10 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
| CN119192275B (zh) * | 2024-08-22 | 2025-05-30 | 湖南玉新药业有限公司 | 一种3-羰基-4-氮杂-5α-雄甾-17β-羧酸化合物的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP3572417B1 (en) | 2011-10-14 | 2025-12-17 | Sage Therapeutics, LLC | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| US9512170B2 (en) * | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| CN117024501A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| KR20250174100A (ko) * | 2018-12-05 | 2025-12-11 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| WO2020132504A1 (en) * | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
-
2019
- 2019-12-20 WO PCT/US2019/067953 patent/WO2020132504A1/en not_active Ceased
- 2019-12-20 CN CN201980085054.3A patent/CN113195512A/zh active Pending
- 2019-12-20 JP JP2021535679A patent/JP7692830B2/ja active Active
- 2019-12-20 KR KR1020217022533A patent/KR20210107050A/ko not_active Ceased
- 2019-12-20 TW TW108147086A patent/TWI848034B/zh active
- 2019-12-20 US US17/416,367 patent/US20220372067A1/en active Pending
- 2019-12-20 EP EP19850836.8A patent/EP3898646B1/en active Active
- 2019-12-20 CA CA3124371A patent/CA3124371A1/en active Pending
- 2019-12-20 BR BR112021012242-7A patent/BR112021012242A2/pt unknown
- 2019-12-20 TW TW113121961A patent/TWI892697B/zh active
- 2019-12-20 AU AU2019403415A patent/AU2019403415B2/en active Active
- 2019-12-20 MX MX2021007504A patent/MX2021007504A/es unknown
-
2021
- 2021-06-18 MX MX2025000126A patent/MX2025000126A/es unknown
- 2021-06-20 IL IL284183A patent/IL284183A/en unknown
-
2024
- 2024-06-11 JP JP2024094279A patent/JP2024107296A/ja active Pending
-
2025
- 2025-11-13 AU AU2025267433A patent/AU2025267433A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514385A5 (enExample) | ||
| JP2022510683A5 (enExample) | ||
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| JP2021527126A5 (enExample) | ||
| JP2021534124A5 (enExample) | ||
| JP2022534424A5 (enExample) | ||
| BR112020008825A2 (pt) | moduladores da via de estresse integrada | |
| JP2017531619A5 (enExample) | ||
| RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
| JP2019520417A5 (enExample) | ||
| RU2020131091A (ru) | Композиции и способы для лечения расстройств цнс | |
| JP2022504607A5 (enExample) | ||
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2020517707A5 (enExample) | ||
| JP2014521653A5 (enExample) | ||
| JP2019526596A5 (enExample) | ||
| BR112020008833A2 (pt) | moduladores da via de estresse integrada | |
| JP2016512531A5 (enExample) | ||
| BR112020008836A2 (pt) | Moduladores da via de estresse integrada | |
| WO2017202816A1 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| JP2021510695A5 (enExample) | ||
| RS61401B1 (sr) | 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za lečenje raka | |
| JP2019520344A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2019501879A5 (enExample) |